TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tarsus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$69.50+1.43 (+2.10%)
Close on Oct 19, 2026
- Market cap
- $3.02B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$72.76M
Long-term debt
Net debt
-$131.83M
After $204.60M of cash
Implied interest rate
12.39%
FY2025 interest ÷ average debt
Interest coverage
-7.9×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Tarsus Pharmaceuticals's annual report. Trading prices and yields need FINRA TRACE data.